March 2017 Monthly Test Updates

Published on 03/01/17

New Test Updates

The below test updates are now live:
  • TL FISH Analysis: Telomere Panel – test discontinued.
  • BCAHP Congenital Adrenal Hyperplasia: Steroid Profile, Quantitative, Dried Blood Spot – test discontinued.
  • BKRBD Krabbe Disease: Galactocerebrosidase Enzyme Activity, Dried Blood Spot – being replaced by a new panel assay in May 2017.
  • DZ Pompe Disease: Acid Alpha-Glucosidase Enzyme Activity, Dried Blood Spot – being replaced by a new panel assay in May 2017.
  • BCQLC Coenzyme Q10, Quantitative, Leukocytes – test discontinued.
  • WA Lynch Syndrome: Microsatellite Instability and Immunohistochemistry – test discontinued.
  • VZ Lynch Syndrome: Immunohistochemistry for MSH6 – test discontinued.
  • VW Lynch Syndrome: Immunohistochemistry - MLH1, MSH2, MSH6, and PMS2 Panel – test discontinued.
  • VY Lynch Syndrome: Immunohistochemistry for MSH2 – test discontinued.
  • VX Lynch Syndrome: Immunohistochemistry for MLH1 – test discontinued.
  • MPMS2 Lynch Syndrome: Immunohistochemistry for PMS2 – test discontinued.
  • VV Lynch Syndrome: Microsatellite Instability – test discontinued.
  • PSONT Natera NIPT – test discontinued.
  • PSOAR Ariosa NIPT – test discontinued.
  • PSOIL Illumina NIPT – test discontinued.
  • AD Chromosome Analysis: Amniotic Fluid - Changing TAT to 7-14 days. Note: TAT is dependent upon sample quality and appropriate cell growth. These cases are processed as STAT. We endeavor to report cases within 7 to 10 days; however, in the case of slow sample growth, this assay may take up to 14 days to complete.
  • CV Chromosome Analysis: Chorionic Villi - Changing TAT to 7-14 days. Note: TAT is dependent upon sample quality and appropriate cell growth. These cases are processed as STAT. We endeavor to report cases within 7 to 10 days; however, in the case of slow sample growth, this assay may take up to 14 days to complete.
  • LS Lysosomal Storage Disease: Panel Enzyme Activity (12 Enzymes), Leukocytes - Updating name, condition description, and methodology to reflect the removal of Krabbe disease from the panel.

New and Updated Gene Panels

Industry-leading number of gene panels

EGL Next Generation Sequencing Panels include comprehensive, evidence-based gene lists, improved turnaround times, and reduced pricing.